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Purpose
The aim of this study is to evaluate the survival rate and prognostic factors of anaplastic 
gliomas according to the 2016 World Health Organization classification, including extent 
of resection (EOR) as measured by contrast-enhanced T1-weighted magnetic resonance 
imaging (MRI) and the T2-weighted MRI. 
Materials and Methods
The records of 113 patients with anaplastic glioma who were newly diagnosed at our 
institute between 2000 and 2013 were retrospectively reviewed. There were 62 cases 
(54.9%) of anaplastic astrocytoma, isocitrate dehydrogenase (IDH) wild-type (AAw), 18 
cases (16.0%) of anaplastic astrocytoma, IDH-mutant, and 33 cases (29.2%) of anaplastic 
oligodendroglioma, IDH-mutant and 1p/19q-codeleted.   
Results
The median overall survival (OS) was 48.4 months in the whole anaplastic glioma group 
and 21.5 months in AAw group. In multivariate analysis, age, preoperative Karnofsky Per-
formance Scale score, O6-methylguanine-DNA methyltransferase (MGMT) methylation sta-
tus, postoperative tumor volume, and EOR measured from the T2 MRI sequence were 
significant prognostic factors. The EOR cut-off point for OS measured in contrast-enhanced 
T1-weighted MRI and T2-weighted MRI were 99.96% and 85.64%, respectively.  
Conclusion
We found that complete resection of the contrast-enhanced portion (99.96%) and more 
than 85.64% resection of the non-enhanced portion of the tumor have prognostic impacts 
on patient survival from anaplastic glioma.    
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Introduction
Anaplastic gliomas, which account for 15%-20% of malig-
nant gliomas [1], have poor prognosis despite modern mul-
timodal treatments. To improve the accuracy of diagnosis 
and treatment, the 2016 World Health Organization (WHO) 
classification changed the three original categories from the 
2007 classification, namely anaplastic astrocytoma, anaplastic 
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oligodendroglioma, and anaplastic oligoastrocytoma. These 
three categories were further subdivided as follows: anaplas- 
tic astrocytoma, isocitrate dehydrogenase (IDH)-mutant 
(AAm); anaplastic astrocytoma, IDH-wildtype (AAw); ana-
plastic astrocytoma, not otherwise specified (NOS); anaplas-
tic oligodendroglioma, IDH-mutant and 1p/19q-codeleted 
(AOmc); anaplastic oligodendroglioma, NOS; and anaplastic 
oligoastrocytoma, NOS [2]. We obtained survival rates accor-
ding to the new classification and examined the associated 
prognostic factors.
Extent of resection (EOR) has been known as an important 
prognosticator in anaplastic gliomas [3,4]. However, many 
studies have focused on only the contrast-enhanced parts of 
tumors observed in T1-weighted magnetic resonance imag-
ing (MRI), despite many cases of anaplastic gliomas that 
are not enhanced or are only partially enhanced in contrast- 
enhanced T1-weighted images. In the present study, we investi- 
gated the tumor volume and EOR in both contrast-enhanced 
T1-weighted MRI and T2-weighted MRI sequences.
The aims of this study were (1) to identify the survival rate 
and prognostic factors in patients with anaplastic gliomas in 
the 2016 WHO classification; (2) to determine whether the 
volumetric measurement of EOR has prognostic value in con-
trast-enhanced T1-weighted MRI and T2-weighted MRI, and 
(3) to determine the prognostically meaningful cut-off value 
of resection volume in each MRI sequence. 
Materials and Methods
1. Patient selection
We performed a retrospective analysis of the medical 
records and MRI features of 113 consecutive patients with 
anaplastic glioma who were newly diagnosed at our institute 
between 2000 and 2013, with neither prior radiotherapy nor 
chemotherapy. We excluded patients with gliomatosis cere-
bri (involving more than three lobes), midline location, and 
malignant transformation of a previously operated low-grade 
glioma. The medical records reviewed included sex, age at first 
diagnosis, preoperative Karnofsky Performance Scale (KPS) 
score, and postoperative treatment (radiotherapy, chemothe- 
rapy) (Table 1).
2. Histopathologic review
We investigated the molecular profiles of all patients inclu-
ding 1p/19q codeletion status, methylation of the O6-methyl-
guanine-DNA methyltransferase (MGMT) promoter and the 
state of IDH mutation. The IDH mutation status was initially 
assessed using immunostaining for the IDH1-R132H muta-
tion. If immunohistochemistry did not show a mutation 
in IDH1-R132H, sequencing of IDH1 codon 123 and IDH2 
codon 172 was performed. The 113 cases (grade III glioma 
based on the 2007 classification) were re-classified using the 
2016 classification system: cases with wild-type IDH were 
classified as AAw, cases with non-codeleted 1p/19q and 
mutated IDH were classified as AAm, and cases with an IDH 
mutation and 1p/19q codeletion were classified as AOmc. 
This re-classification identified 62 cases of AAw, 18 cases of 
AAm, and 33 cases of AOmc. All pathological and molecular 
data were reviewed by a single pathologist (S.H.K.). 
3. Imaging evaluation
MRI sequences, including T2-weighted, fluid-attenuated 
inversion recovery (FLAIR) and contrast-enhanced T1-wei-
ghted, were obtained preoperatively, postoperatively, and at 
regular follow-ups. Two experienced radiologists reviewed 
all patients’ MRI data. Manual segmentation was performed 
to measure the tumor and resection volumes. We used Osi-
riX software (Pixmeo SARL, Bernex, Switzerland) to meas-
ure tumor volumes and EOR. Tumor volume was estimated 
based on the area of increased signal intensity on the con-
trast-enhanced T1-weighted images (enhancing lesions) or 
T2-weighted images (non-enhancing lesions). We tried to 
exclude any regions with cerebral edema on the T2-weighted 
images. The non-enhancing tumor was defined with regions 
of T2 hyperintensity (less than cerebrospinal fluid signal) that 
were associated with mass effect and architectural distortion, 
including blurring of the gray matter/white matter interface. 
Edema needed to be greater in signal than the non-enhanc-
ing tumor and lower than the cerebrospinal fluid on T2. The 
resection extent was calculated using early postoperative 
images (< 48 hours). EOR was calculated with the following 
equation: (preoperative tumor volume–postoperative tumor 
volume)/preoperative tumor volume. With respect to tumor 
location, deep lesions were defined as those that involved the 
brainstem, thalamus, basal ganglia, and the insula; superfi-
cial lesions involved only the cortex outside the insula.
4. Statistical analyses
We analyzed overall survival (OS) and progression-free 
survival (PFS) according to the specific pathology type using 
Kaplan-Meier curves and log-rank tests. To identify factors 
associated with PFS and OS, univariate and a multivariate 
Cox proportional regression analyses with stepwise methods 
(entry and exit criteria of p < 0.05) were performed, using the 
time from surgery to progression or death. Age, preopera-
tive KPS score, tumor volume, and EOR were evaluated as 
continuous variables. OS was defined as the time from sur-
gery to death from any cause or the last follow-up. PFS was 
defined as the time from surgery to the first instance of radio-
logical signs of progression and/or deteriorated neurologi-
cal status or death. We estimated optimal cut-off values for 
the dichotomization of the clinical outcome variable based 
on time-to-event data using the technique devised by Contal 
and O’Quigley [5]. The optimal cut-off point was selected by 
maximizing the hazard ratio. p-value < 0.05 was considered 
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statistically significant. All statistical procedures were per-
formed using SAS for Windows ver. 9.4 (SAS Institute Inc., 
Cary, NC).  
5. Ethical statement
All methods were performed in accordance with the ethi- 
cal guidelines of the 1975 Deceleration of Helsinki, as revi- 
sed in 1983, and was approved by the institutional review 
board of Severance Hospital (Yonsei University Health Sys-
tem, Severance Hospital, 4-2019-0181). The written infor- 
med consent was waived by the institutional review board 
that approved this study’s protocol because all the informa-
tion was tabulated in anonymized and de-identified fashion.
Results
1. Patient characteristics
The clinical information of all 113 patients are listed in 
Table 1, stratified by the 2016 WHO classification. There were 
62 patients (54.9%) in the AAw group, 18 (16.0%) in the AAm 
group, and 33 (29.2%) in the AOmc group. The median age 
at first diagnosis in the whole cohort was 40 years (range, 18 
to 82 years). In total, 102 patients (90.3%) received postop-
erative radiotherapy and 59 (52.2%) received chemotherapy. 
Among the chemotherapy regimens, 15 cases (13.3%) were 
treated with PCV (procarbazine, lomustine, and vincristine) 
and 41 (36.3%) with temozolomide. The postoperative treat-
ment modalities are also presented in Table 1. MGMT pro-
moter methylation was detected in 64 cases (56.6%) of the 
Table 1.  Baseline patient characteristics
 AAw AAm AOmc Total
No. of patients 62 (54.9) 18 (16.0) 33 (29.2) 113 (100)
Age, median (range, yr) 48 (18-82) 36 (18-71) 45 (24-76) 40 (18-82)
Sex, female/male 27/35 8/10 14/19 49/64
Preoperative KPS, median (range) 80 (40-90) 80 (80-90) 80 (70-100) 80 (40-100)
Postoperative treatment    
    CCRT 5 (4.4) 1 (0.9) 0 ( 6 (5.3)
    CCRT → CT 15 (13.3) 1 (0.9) 9 (8.0) 25 (22.1)
    RT → CT 12 (10.6) 7 (6.2) 9 (8.0) 28 (24.8)
    RT 20 (17.7) 8 (7.1) 15 (13.3) 43 (38.1)
    None 4 (3.5) 0 ( 0 ( 4 (3.5)
    Unknown 6 (5.3) 1 (0.9) 0 ( 7 (6.2)
Chemotherapy regimen    
    PCV 9 (8.0) 1 (0.9) 5 (4.4) 15 (13.3)
    TMZ 21 (18.6) 8 (7.1) 12 (10.6) 41 (36.3)
    Othersa) 2 (1.8) 0 ( 1 (0.9) 3 (2.7)
MGMT promoter status    
    Methylated 20 (17.7) 15 (13.3) 29 (25.7) 64 (56.6)
    Unmethylated 41 (36.3) 3 (2.7) 4 (3.5) 48 (42.5)
    Missing 1 (0.9) 0 ( 0 ( 1 (0.9)
Tumor location    
    Deep 24 (21.2) 4 (3.5) 5 (4.4) 33 (29.2)
    Superficial 32 (28.3) 12 (10.6) 26 (23.0) 70 (61.9)
Volumetric analysis, mean (range)    
    Preoperative (T1CE, cm3) 14.6 (0.0-117.8) 3.2 (0.0-14.8) 18.0 (0-112.2) 13.8 (0.0-117.8)
    Preoperative (T2, cm3) 48.7 (0.8-197.2) 83.9 (13.5-232.9) 87.1 (6.2-212.3) 51.6 (0.8-232.9)
    Postoperative (T1CE, cm3) 2.62 (0-24.4) 0.0 (0-0) 0.1 (0-2.5) 1.0 (0-24.4)
    Postoperative (T2, cm3) 19.3 (0-166.5) 4.9 (0.7-27.3) 4.3 (0-26.9) 9.9 (0-166.5)
    Extent of resection (T1CE, %) 81.5 (0-100) 100.0 (100-100) 95.9 (41.2-100) 90.6 (0-100)
    Extent of resection (T2, %) 75.4 (0-100) 92.5 (52.7-100) 95.4 (76.5-100) 87.4 (0-100)
Values are presented as number (%) unless otherwise indicated. AAw, anaplastic astrocytoma, IDH-wildtype; AAm, anaplastic astrocytoma, 
IDH-mutant; AOmc, anaplastic oligodendroglioma, IDH-mutant, and 1p/19q-codeleted; KPS, Karnofsky Performance Scale; CCRT, concur-
rent chemo-radiation therapy; CT, chemotherapy; RT, radiation therapy; PCV, procarbazine, lomustine, and vincristine; TMZ, temozolo-
mide; MGMT, O6-methylguanine-DNA methyltransferase; T1CE, T1-weighted contrast-enhanced magnetic resonance imaging (MRI); T2, 
T2-weighted MRI. a)Others included fluorouracil +carboplatin, vincristine, and lomustine.
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whole cohort, 20 cases (17.7%) in the AAw subgroup, 15 
cases (13.3%) in the AAm subgroup, and 29 cases (25.7%) in 
the AOmc subgroup.
2. Volumetric analysis
The mean tumor volumes in the contrast-enhanced T1-
weighted and T2-weighted MRI sequences were respectively 
13.8 cm3 (range, 0.0 to 117.8 cm3) and 51.6 cm3 (range, 0.8 
to 232.9 cm3) preoperatively, and 1.0 cm3 (range, 0.0 to 24.4 
cm3) and 9.9 cm3 (range, 0.0 to 166.5 cm3) postoperatively. 
The EOR measured in contrast-enhanced T1-weighted MRI 
(EOR-T1CE) was 90.6% (range, 0% to 100%), while it was 
87.4% (0.0%-100%) in the T2-weighted MRI sequence. In our 
study biopsies were performed in 25 patients (22.1%). 
3. Survival
After a median follow-up period of 66.1 months, the 
median OS was 48.4 months (95% confidence interval [CI], 
15.1 to 81.7) for all patients and 21.5 months (95% CI, 17.2 to 
25.8) in the AAw subgroup (Table 2, Fig. 1). The median OS 
was not reached in the other subgroups since more than half 
of the patients were still alive at the last follow-up. OS values 
for years 1-5 are presented in Table 2. PFS was 31.8 months 
(95% CI, 17.6 to 46.2) for all patients, 16.4 months (95% CI, 
12.6 to 21.0) in the AAw subgroup, and 130.0 months (95% 
CI, 0.0 to 269.8) in the AOmc subgroup (Table 2, Fig. 2). PFS 
values for years 1-5 are presented in Table 2.  
4. Prognostic factors
In univariate analysis, age, preoperative KPS score, tumor 
location, MGMT methylation status, postoperative residual 
tumor volume measured in contrast-enhanced T1-weight-
ed MRI (RTV-T1CE), postoperative residual tumor volume 
measured in T2-weighted MRI (RTV-T2), EOR-T1CE, and 
EOR measured in T2-weighted MRI (EOR-T2) were statisti-
cally significant prognostic factors for OS and PFS (Table 3). 
In the multivariate analysis, age, preoperative KPS, MGMT 
methylation status, RTV-T1CE, RTV-T2 and EOR-T2 were 
Table 2.  Overall survival (OS) and progression-free survival (PFS)
Group Median (mo)
   Survival rate (%)
  1-Year  2-Year  3-Year  4-Year  5-Year 
OS  
    GIII all   48.4 84.8 64.9 55.6 50.7 45.3
    AAw   21.5 74.1 64.0 46.6 28.3 14.4
    AAm n.r. 69.3 55.4 55.4 55.4 55.4
    AOmc n.r. 96.3 85.9 85.9 85.9 85.9
PFS      
    GIII all   31.8 76.7 58.7 49.2 43.1 41.8
    AAw   16.4 80.6 64.5 45.7 25.8   9.0
    AAm n.r. 88.9 83.0 83.0 62.2 62.2
    AOmc 130.0 96.4 92.4 82.6 82.6 82.6
GIII, grade III glioma; AAw, anaplastic astrocytoma, IDH-wildtype; AAm, anaplastic astrocytoma, IDH-mutant; n.r., not reached; AOmc, 
anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
Fig. 1.  Overall survival. (A) Kaplan-Meier representation of overall survival time for the entire group of 113 patients. (B) Kaplan-Meier 
representation of overall survival time for the AAw, AAm, AOmc each group. AAm, anaplastic astrocytoma, IDH-mutant; AAw, anaplastic 
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also statistically significant prognostic factor for OS, while 
age, MGMT methylation status, RTV-T1CE, RTV-T2, and 
EOR-T2 were statistically significant prognostic factors for 
PFS (Table 4).  
5. Cut-off value of EOR
In cut-off value analysis using the Contal and O’Quigley 
method, age < 51 years, complete resection of the enhanced 
portion (99.96%), and more than 85.64% resection of the non- 
enhanced tumor portion showed prognostic impacts on 
OS in patients with anaplastic gliomas (Table 5, Fig. 3). As 
for PFS, age < 55 years, 72.73% resection of the contrast- 
enhanced portion, and 84.88% resection of the non-enhanced 
tumor portion demonstrated prognostic impacts (Table 5, 
Fig. 4). 
Discussion
Despite multimodal treatment with surgery, radiotherapy, 
 and chemotherapy, the prognosis for anaplastic glioma 
is poor. Several reports published in the past decade have 
shown survival times ranging from 19 months to 14.7 years 
for anaplastic gliomas [3,4,6-11]. Because of these varied 
prognoses, a new WHO 2016 classification, based on molec-
ular markers, has been developed to promote more detailed 
and accurate diagnosis. Our study of 113 patients with ana-
plastic gliomas analyzed the survival, prognostic factors, and 
the cut-off value of extent of tumor resection, according to 
the 2016 WHO classification. Moreover, we found that the 
OS after surgery was 48.4 months for all anaplastic gliomas 
Fig. 2.  Progression-free survival. (A) Kaplan-Meier representation of progression-free survival time for the entire group of 113 patients. 
(B) Kaplan-Meier representation of progression-free survival time for the AAw, AAm, AOmc each group. AAm, anaplastic astrocytoma, 













































Table 3.  Univariate analysis of prognostic factors
                            OS                           PFS
 HR (95% CI) p-value HR (95% CI) p-value
Age 1.025 (1.008-1.042) 0.004 1.022 (1.006-1.038) 0.008  
Sex 1.248 (0.729-2.135) 0.419 1.436 (0.856-2.408) 0.170
Preoperative KPS score 0.911 (0.866-0.958) < 0.001 0.932 (0.893-0.972) 0.001
Deep location 0.333 (0.193-0.577) < 0.001 0.316 (0.186-0.537) < 0.001
MGMT methylation status 0.405 (0.236-0.694) 0.001 0.418 (0.251-0.696) 0.001
Chemotherapy 0.727 (0.427-1.237) 0.240 0.744 (0.450-1.231) 0.250
Preoperative T1CE tumor volume 1.006 (0.998-1.015) 0.160 1.005 (0.996-1.014) 0.296
Preoperative T2 tumor volume 0.995 (0.990-1.000) 0.073 0.995 (0.991-1.000) 0.057
Postoperative T1CE tumor volume 1.155 (1.085-1.229) < 0.001 1.119 (1.058-1.184) < 0.001
Postoperative T2 tumor volume 1.019 (1.009-1.030) < 0.001 1.015 (1.006-1.025) 0.001
EOR (T1CE %) 0.985 (0.973-0.997) 0.013 0.986 (0.974-0.998) 0.018
EOR (T2 %) 0.976 (0.964-0.987) < 0.001 0.977 (0.966-0.988) < 0.001
OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; KPS, Karnofsky performance status; MGMT, 
O6-methylguanine-DNA methyltransferase; T1CE, T1-weighted contrast-enhanced magnetic resonance ima-ging (MRI); T2, T2-weighted 
MRI; EOR, extent of resection.
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and 21.5 months in the AAw subgroup (Table 2).
Previously reported prognostic factors for anaplastic glio-
ma include advanced patient age, preoperative neurological 
status, KPS, symptom duration, tumor location, EOR, adju-
vant therapy (including radiation therapy and chemothera-
py), preoperative MRI findings, as well as various molecular 
markers including IDH and PTEN mutations, 1p/19q code-
letion, epidermal growth factor receptor (EGFR) amplifica-
tion, and MGMT methylation [4,7-9,12-15]. The importance 
of these molecular markers for prognosis was reflected in 
the new WHO classification of 2016, which has had a great 
impact on the diagnostic criteria. Here, we have confirmed 
several prognostic factors including age, preoperative KPS, 
MGMT methylation status, postoperative tumor volume, and 
 EOR.
Aggressive tumor resection can be dangerous for the pati- 
ent’s neurologic function, especially when the tumor is loca-
ted deep inside the brain. Thus, when evaluating the asso-
ciation between survival and the EOR, it is important to take 
the tumor’s location into account. In our series, tumor loca-
tion was a statistically significant prognostic factor in uni-
variate analysis, but its effect was lost in multivariate analy-
sis. In addition, the association between preoperative tumor 
volume and survival rate was not statistically significant. 
These results suggest that the degree of surgical removal has 
a greater effect on the prognosis than the preoperative size 
and location.
In our univariate analysis, postoperative residual tumor 
volume and EOR were statistically significant prognostic 
factors for OS and PFS. This suggests that the extent of surgi-
cal resection and remaining tumor volume after surgery may 
have greater impacts on prognosis than preoperative vol-
ume (Table 3). However, in multivariate analysis, RTV-T1CE, 
RTV-T2, and EOR-T2 were statistically important prognostic 
factors (Table 4). The statistical insignificance of EOR-T1CE 
in multivariate analysis appears to be an effect of T2 lesions. 
Basically, T1 contrast-enhanced lesions are included in T2 
lesions. Therefore, as shown in previous studies, we hypoth-
esize that the EOR-T1CE still has significant prognostic val-
ue, and a study of the EOR cut-off value can be performed.
Malignant astrocytomas, including anaplastic glioma and 
glioblastoma multiforme, are difficult to resect curatively 
because of their invasive and infiltrative nature to the sur-
rounding tissue [16]. This is especially difficult if the tumor is 
located in a functionally important region. However, micro-
surgical resection is a very important factor in the treatment 
of glioma, and maximal safe resection is known to be a good 
prognostic factor for all grades of gliomas [17-22].
In past, some studies had reported that there is no rela-
tionship between the EOR and survival in anaplastic gliomas 
Table 4.  Multivariate analysis of prognostic factors
Variable
                            OS                           PFS
 HR (95% CI) p-value HR (95% CI) p-value
Age 1.068 (1.023-1.115) 0.003 1.073 (1.029-1.118) 0.001 
Preop KPS 0.889 (0.805-0.981) 0.019 0.921 (0.847-1.001) 0.052
Deep location 0.302 (0.083-1.101) 0.070 0.334 (0.104-1.077) 0.066
MGMT methylation status 0.150 (0.037-0.613) 0.008 0.092 (0.022-0.381) 0.001
Postoperative T1CE tumor volume 1.301 (1.056-1.602) 0.013 1.335 (1.071-1.663) 0.010
Postoperative T2 tumor volume 1.054 (1.009-1.100) 0.019 1.076 (1.027-1.129) 0.002
EOR (T1CE %) 0.999 (0.975-1.024) 0.925 0.993 (0.969-1.017) 0.578
EOR (T2 %) 0.951 (0.915-0.988) 0.010 0.942 (0.907-0.978) 0.002
OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; KPS, Karnofsky performance status; MGMT, 
O6-methylguanine-DNA methyltransferase; T1CE, T1-weighted contrast-enhanced magnetic resonance imaging (MRI); T2, T2-weighted 
MRI; EOR, extent of resection.
Table 5.  Cut-off point (Contal and O’Quigley method)
Variable
        OS    PFS
 Cut point HR (95% CI) p-value Cut point HR (95% CI) p-value
Age ≥ 51 2.911 (1.880-4.508) < 0.001 ≥ 55 2.971 (1.942-4.545) < 0.001
EOR (T1CE %) ≥ 99.957 0.284 (0.154-0.524) < 0.001 ≥ 72.727 0.370 (0.227-0.602) < 0.001
EOR (T2 %) ≥ 85.643 0.141 (0.075-0.267) < 0.001 ≥ 84.883 0.193 (0.112-0.331) < 0.001
OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; EOR, extent of resection; T1CE, T1-weighted 
contrast-enhanced magnetic resonance imaging (MRI); T2, T2-weighted MRI.
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[23,24]. However, recent studies have revealed that there is 
a relationship between the EOR and survival in anaplastic 
gliomas [3,25,26]. We performed volumetric analysis in the 
present study, confined to anaplastic gliomas, which have 
heterogenous features in MRI. A considerable proportion of 
anaplastic gliomas do not show contrast enhancement in T1- 
weighted MRI [15,17]. Therefore, to obtain a more accurate 
tumor volume, both abnormal T2/FLAIR hyperintense lesions 
as well as T1-weighted contrast-enhanced lesions should be 
considered. Previous studies analyzed EOR by combining 
tumor volume measured in T1-weighted contrast-enhanced 
images with that of T2/FLAIR image or T2 image alone 
[25,26]. To obtain more accurate information, we analyzed 
T2-weighted and T1 contrast-enhanced images separately 
and attempted to determine whether the EOR of each sequ-
ence affects survival rate.
Previous studies have found EOR thresholds of 76% in 
GIII glioma, 90% in GII glioma, 100% contrast enhancing 
resection with additional 53.21% of FLAIR hyperintense 
lesion in glioblastoma, and 53% in anaplastic astrocytoma 
and anaplastic oligoastrocytoma [18,22,25,26].
We investigated the cut-off value for the EOR on each MRI 
sequence (Table 5). The cut-off value of EOR affecting OS was 
99.96% in contrast-enhanced T1-weighted MRI and 85.64% 
in T2-weighted MRI, so we propose that these EOR values 
are important for anaplastic gliomas. The use of multiple 
MRI sequences for suggesting the cut-off value of the volu-
metric EOR represents a strength of our study in the era of 
molecular glioma classification.
Age has already been identified as an important prognos-
tic factor in several studies [3,7,24]. For example, a study has 
reported that an age of 65 years or older is a poor prognostic 
factor [27]. In the present study, we confirmed that age is an 
important factor affecting survival: 51 years old was the cut-
off value that influenced the OS rate, while a cut-off of 55 
years affected PFS.
Our study has some limitations. First, because of its ret-
rospective nature from a single institution, there may be a 
selection bias of the patients. A few cases were excluded 
because of inadequate information of MRI available for 
Fig. 3.  Overall survival. (A) Kaplan-Meier representation of overall survival time according to EOR (T1CE). (B)  Kaplan-Meier representa-
tion of overall survival time according to EOR (T2). EOR, extent of resection; T1CE, T1-weighted contrast-enhanced magnetic resonance 
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Fig. 4.  Progression-free survival. (A) Kaplan-Meier representation of progression-free survival time according to EOR (T1CE). (B)  Kaplan-
Meier representation of progression-free survival time according to EOR (T2). EOR, extent of resection; T1CE, T1-weighted contrast-en-
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review. However, we tried to analyze a uniform patient popu- 
lation by examining consecutive patients. Second, there may 
be measuring bias. Because we measured T2-weighted hyper-
intense lesions separately, cerebral edema, ischemic change, 
and contusions may have been included to tumor volume in 
some degree. Third, patients have received various chemo-
therapeutic agents although the regimens of chemotherapy 
did not have a statistical significance in univariate analysis. 
And the postoperative radiation therapy was not controlled. 
In the future, more controlled multicenter validation studies 
are required.
In conclusion, the median OS was 48.4 months in the whole 
anaplastic glioma group and 21.5 months in the AAw group. 
We have also revealed that complete resection (more than 
99.96%) of tumor volume measured in contrast-enhanced 
T1-weighted MRI, and more than 85.64% of tumor resection 
measured in T2-weighted MRI, have prognostic impacts on 
the survival of patients with anaplastic gliomas. Therefore, 
gross-total resection of at least the contrast-enhanced part of 
a lesion should be performed to prolong survival in anaplas-
tic glioma patients. 
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